India Vaccine Production

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

Devendra Fadnavis on Wednesday said when Prime Minister Narendra Modi was facilitating vaccine production in the country during the pandemic, the then-MVA government in the state was indulging in alleged scams.

Praising the work done by the founder of the Serum Institute of India (SII), in the field of vaccine production, founder of Nationalist Congress Party (NCP) Sharad Pawar demanded that Cyrus Poonawalla be honoured with the Bharat Ratna award.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

Nasal Covid-19 vaccines could help to bring the Covid-19 pandemic under control, the World Health Organization said Wednesday after homegrown products were approved in India and China.

The Union Finance Ministry contributed more than Rs 900 crore to COVID vaccine development under 'Mission COVID Suraskha' resulting in India becoming a leader in vaccine production, said a top official.

At a special meeting of India-ASEAN foreign ministers in Delhi, India and ASEAN resolved to expand cooperation in key sectors such as trade, connectivity, defence, vaccine production and clean energy, etc.

Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply

Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.

Global forecasting firm Oxford Economics on Tuesday revised India's GDP (gross domestic product) growth forecast to 7.9 per cent from earlier 7.8 per cent for the current financial year 2021-22 (FY22), citing more durable recovery and higher Covid-19 vaccination rates.

Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

Devendra Fadnavis on Wednesday said when Prime Minister Narendra Modi was facilitating vaccine production in the country during the pandemic, the then-MVA government in the state was indulging in alleged scams.

Praising the work done by the founder of the Serum Institute of India (SII), in the field of vaccine production, founder of Nationalist Congress Party (NCP) Sharad Pawar demanded that Cyrus Poonawalla be honoured with the Bharat Ratna award.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

Nasal Covid-19 vaccines could help to bring the Covid-19 pandemic under control, the World Health Organization said Wednesday after homegrown products were approved in India and China.

The Union Finance Ministry contributed more than Rs 900 crore to COVID vaccine development under 'Mission COVID Suraskha' resulting in India becoming a leader in vaccine production, said a top official.

At a special meeting of India-ASEAN foreign ministers in Delhi, India and ASEAN resolved to expand cooperation in key sectors such as trade, connectivity, defence, vaccine production and clean energy, etc.

Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply

Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.

Global forecasting firm Oxford Economics on Tuesday revised India's GDP (gross domestic product) growth forecast to 7.9 per cent from earlier 7.8 per cent for the current financial year 2021-22 (FY22), citing more durable recovery and higher Covid-19 vaccination rates.

Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine